Cloud Prophecy

The proposed concept was developing a worldwide collection of atmospheric infectious disease sampling nodes, conceived back in 2016 with the support of a leading member of Congress, Rosa DeLauro. 

Utilizing electrospray ionization, a technology developed by Dr. John Fenn at Yale University resulting in a 2002 Nobel Prize in Chemistry, the inventor of the ambient infectious disease system leveraged his work in collaboration with Dr. Fenn to define how nodes can be utilized to detect pathogens and yield biological data worldwide in real time. Having independent yet linked web nodes coupled to a new infectious disease world database offers the opportunity for real-time detection of any new and possibly spreading disease. 

Genetic data and other characteristics can be acquired, and using AI, provide information concerning the threat of any potentially infectious agent. It is currently the intent of the system to have multiple countries participate to create the new collection system and analytic instrumentation of each sampling node design. 

The inventor(s) of the system who collaborated with John Fenn, my , Dr. Joseph Bango, have several issued U.S. patents, specifically patent 11,300,484 and patent 11,804,033. It is important to leverage the system design with as many countries as possible, and establish an international organization who can lead future development and control of a system for infectious disease monitoring and interaction development. 

The intellectual property and other new concepts need to be assigned, and we are willing, to the international organization and all medical research companies and universities for the common good of humanity.

Viruses and bacteria float in the air as part of respiratory droplets derived from human & animal breathing and speech and sound. The lifetime of potential infectious agents is dependent on droplet size, ambient temperature, air flow, and location of other breathing species in the region of potential pathogens. 

The distribution of infectious potential of ambient droplet species was studied and interpreted by Dr. Lydia Bourouiba at MIT. The proposed system for detection of infectious disease has been inspired by Dr. Bourouiba's extensive research discoveries. The challenge for the proposed system is to collect micro airborne droplets that contain said potential pathogens, and nondestructively attract and collect the sample species for subsequent evaluation so that definitive data can be uploaded to an infectious disease web-based network. 

Using an "electrospray" source, the technology invented by Nobel Laureate Dr. John Fenn, produces charged droplets which are sprayed through the ambient air sampling system. The electrical charges on the surface of an electrospray attract and capture the droplets that were from human breathing and talking, and the samples can now be introduced into a system that can conduct genetic and other sample analysis. The resulting data is fed to a database, and with AI and world-based analytical determination, the type of potential infectious agents can be identified, recorded, and shared.

The proposed ambient infectious disease healthcare system offers an option for the global target population. 

At present, our world is underserved in that evolving local infectious disease is not ascertained until a high enough concentration has been achieved. The difficulty includes the time interval for identifying the genetic data of the infectious agent and where and when disease has been transpiring. 

The proposed system offers a new and extensive method of sample collection, interrogation, and worldwide data distribution, helping to mitigate the spread of infectious disease.

Our team has many years of electrospray experience, past collaboration with MIT pathogen airborne distribution research, and the development of potential pathogen collection and analysis approaches defined in issued U.S. patents, with more to come.

Our firm has had decades of electrospray-based mass spectrometric and other electrospray experience working with the late Dr. John Fenn, and received multiple government-based research contracts. 

We have established how electrospray can be used to collect and distribute airborne pathogens contained in droplets and introduce potential pathogens into a partial pressure analytical chamber. 

We are presently seeking additional support for genetic sequencing tools for the system, and collaboration to achieve network nodes and a telemetry-based system. No customers exist so far, but the potential is significant. 

It is our intent to share technology with a world team, with the innovation to become an international organization.

We are seeking from MIT Solve an international team we can help develop & support, that can receive the technology concepts and patents, that can allow a pathway for financial, legal, and can yield international interest to develop the proposed world infectious disease detection and monitoring system. 

The basic idea for a series of atmospheric pathogen collection nodes, and the capability of using electrospray, nanopore genetic sequencing options, artificial intelligence, and more technical capabilities, offers a means to achieve a remarkable and highly useful means of early real time detection of any possible pathogen threats, making sure humans never experience an epidemic or pandemic ever again, thus leading to improved health for all countries in the future.

Realtime global capture and detection of airborne pathogens is in itself innovative. However, when we add Ai, global databases of known pathogens, as well as some of our other innovations for creating a cost effective global node network for detection, things start looking very innovative. The application for this technology and eventual infrastructure can be used, on or off-planet, to detect other substances we have yet to discover. 

The current detection of airborne pathogens is obviously rudimentary, given our revelations into the beginnings and impact of Covid-19. Our innovation if deployed, would have identified the first-contact by region and would have detected the variations and evolution of the virus by region as well as offered an impact rating on its spread over time and location. 

If we can detect one airborne pathogen, faster and more accurately at lower cost than anyone else, then we have achieved the start of our journey to a robust global platform and service for the benefit of the world. Additionally, data shows that health impacts the poor and underserved communities and countries more than any other groups, therefore, our technology and innovation would provide the most benefit to the underserved first.

Using an "electrospray" source, the technology invented by Nobel Laureate Dr. John Fenn, produces charged droplets which are sprayed through the ambient air sampling system. The electrical charges on the surface of an electrospray attract and capture the droplets that were from human breathing and talking, and the samples can now be introduced into a system that can conduct genetic and other sample analysis. The resulting data is fed to a new internet database, and with AI and world-based analytical determination, the type of potential infectious agents can be identified, recorded, and shared.

full-time staff = 5

part-time staff = 2 

contractors = 2

other = 2

approximately 2016 

Our team consist of Italian, Middle Eastern, and Europeans with various religions, backgrounds, hardships, and experiences. 

Our combined team currently speaks about 5-7 languages. 

We know that diversified teams produces better solutions that impact the globe in a more equitable and inclusive nature. As such one of our core principles in hiring is to ensure we hire the best talent with the most diverse backgrounds.

Tiered subscription, licensing or patents and services.

We are currently continuing to prototype the model and have started engaging with venture investment who has shared high interest in our work. 

We have tested a tiered subscription model for our users (typically academic, healthcare, research, labs, bio firms, etc.), as well as open to other licensing models.